ClinicalTrials.gg
CompletedNCT04347239Updated Oct 15, 2025Results posted

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

A Phase 2 interventional study of Placebo and Leronlimab (700mg) in Coronavirus Disease 2019, sponsored by CytoDyn, Inc.. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
484
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
311th of 1,321
484 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
141st of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 311th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 141st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.

Read the detailed description

This was a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.

A single arm, non-randomized, open-label phase was added to the protocol after completion of enrollment in the randomized phase of the study.

The study had three phases: Screening Period, Treatment Period, and Follow-Up Period.

03

Conditions studied

  • Coronavirus Disease 2019

Browse trials for

Keywords

  • COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adult ≥ 18 years of age at time of screening.
  2. Subjects hospitalized with severe or critical illness caused by coronavirus 2019 infection as defined below:

    A. Severe Illness:

    - Diagnosed with COVID-19 by standard reverse transcriptase polymerase chain reaction (RT-PCR) assay or equivalent testing within 5 days of screening

    AND

    Symptoms of severe systemic illness/infection with COVID-19:

    - At least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe lower respiratory symptoms including dyspnea at rest or respiratory distress

    AND

    Clinical signs indicative of severe systemic illness/infection with COVID-19, with at least 1 of the following:

    - respiration rate (RR) ≥ 30, heart rate (HR) ≥ 125, saturated oxygen (SaO2) \<93% on room air or requires > 2L oxygen by nasal canula (NC) in order maintain SaO2 ≥93%, PaO2/FiO2 \<300 (ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen)

    AND

    - None of the following: Respiratory failure (defined by endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, or clinical diagnosis of respiratory failure in setting of resource limitations), Septic shock (defined by systolic blood pressure (SBP) \< 90 mm Hg, or Diastolic BP \< 60 mm Hg), Multiple organ dysfunction/failure

    B. Critical Illness:

    - Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days of screening

    AND

    Evidence of critical illness, defined by at least 1 of the following:

    - Respiratory failure defined based on resource utilization requiring at least 1 of the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, extracorporeal membrane oxygenation (ECMO), or clinical diagnosis of respiratory failure (in setting of resource limitation)

    OR

    - Shock (defined by SBP \< 90 mm Hg, or Diastolic BP \< 60 mm Hg or requiring vasopressors)

    OR

    -Multiple organ dysfunction/failure

  3. Subject, if intubated, positive end expiratory pressure (PEEP) \<15 cmH2O with PaO2/FiO2 >150 mmHg.
  4. (ECG) with no findings as assessed by the Investigator
  5. Subject (or legally authorized representative) provides written prior to initiation of any study procedures.
  6. Understands and agrees to comply with planned study procedures.
  7. Women of and their partner must agree to use at least one highly effective method of (e.g., hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with do-not-resuscitate (DNR) and/or do-not-intubate (DNI) orders or expected to be made DNR/DNI in setting of resource limitations or family wishes.
  2. Not a candidate for dialysis or continuation of care (or full medical support) in setting of resource limitations.
  3. Subject on continuous vasopressors (at the dose of norepinephrine >20μg/min and/or vasopressin >0.04 units/kg/min) for >48 hours at time of screening.
  4. Subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (PRO 140) are not eligible.
  5. Inability to provide or to comply with test requirements
  6. Consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment
  7. Pregnancy or breast feeding
  8. Subject participating in another study with for an treatment for COVID-19.

Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
484 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Syringes containing normal saline for injection were prepared by an unblinded pharmacist at the clinical sites for use as the placebo.

    Drug: Placebo

  • Experimental
    700mg Leronlimab

    Each vial of active contains 350mg of leronlimab at a concentration of 175mg/ml (nominal 2mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.

    Drug: Leronlimab (700mg)

  • Experimental
    700mg Leronlimab Open Label

    Each vial of active contains 350mg of leronlimab at a concentration of 175mg/ml (nominal 2mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.

    Drug: Leronlimab (700mg)

Interventions

  • DrugPlacebo

    Placebo

  • Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

    Also known as: PRO 140

06

What researchers measure

Primary outcomes

  1. All-cause Mortality at Day 28

    Incidence of mortality at day 28

    Time frame: Mortality at day 28 (Visit 2, start of treatment = day 0)

Secondary outcomes

  1. All-cause Mortality at Day 14

    Day 0 refers to the data of randomization/first treatment.

    Time frame: Mortality at day 14 (initiation of treatment = day 0)

  2. Proportion of Patients Achieving a Category of 6 or Higher on the Ordinal Scale at Days 14 and 28 (on a 7 Point Ordinal Scale).

    Evaluation of the clinical status of participants at Day 28 was assessed with a 7-level ordinal scale (OS) (with higher score indicating better outcome). The OS of patient health status ranged from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. The study enrolled hospitalized patients with an OS Score of 2, 3, or 4 at baseline. The OS score of 6 refers to a participant who is not hospitalized with limitation on activities and 7 refers to not hospitalized with no limitations on activities.

    Time frame: Change from baseline to days 14 and 28

  3. Change in Clinical Status of Subjects at Day 28 (on a 7 Point Ordinal Scale)

    Evaluation of the clinical status of participants at Day 28 was assessed with a 7-level ordinal scale (OS) (with higher score indicating better outcome). The OS of patient health status ranged from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. The study enrolled hospitalized patients with an OS Score of 2, 3, or 4 at baseline. Baseline is last available value before treatment. Change from baseline is based on patients with paired values. The p value is from rank ANCOVA model adjusted for stratification factor and age using imputed data. All results and change from baseline are based on the result of multiple imputation.

    Time frame: Change from start of treatment (baseline) to day 28

  4. Length of Hospital Stay

    Length of Hospital Stay measured in days

    Time frame: Timeframe is from screening visit to end of treatment (visit 5)

Other outcomes

  1. All-Cause Mortality at Day 14 in the Critically Ill Population

    All-cause mortality at day 14 in the critically ill population. Day 0 refers to the date of randomization/first treatment.

    Time frame: Mortality at day 14 (initiation of treatment = day 0)

07

Results

Posted Aug 27, 2025
Limitations and caveats
The outcome and safety data came from a report from the contract research organization that oversaw the study. A review of 64 Case Report Forms for the open label portion of the study indicated that over 70% contained no information about adverse events, therefore the adverse events for the open label portion of the study may be underreported.

Participant flow

Participants were enrolled at study sites in the United States. First patient was enrolled into Part 1 of the study (blinded portion) on 16-April-2020. Data submitted represent analysis performed on data collected after all patients completed the Follow Up period.

Blinded Portion
Participant flow — Blinded Portion
MilestonePlacebo700mg Leronlimab700mg Open Label
Started1292650
Completed1252590
Not completed460
Withdrew: Pt randomized to study but withdrew consent before treatment with investigational product604
Open Label
Participant flow — Open Label
MilestonePlacebo700mg Leronlimab700mg Open Label
Started0090
Completed0089
Not completed001
Withdrew: Pt enrolled but withdrew consent prior to dosing100

Outcome measures

PrimaryAll-cause Mortality at Day 28

Incidence of mortality at day 28

Time frame:
Mortality at day 28 (Visit 2, start of treatment = day 0)
Reported as:
Count of participants · Participants
All-cause Mortality at Day 28
Participants700mg LeronlimabPlacebo700mg Open Label
Mortality522723
Survival2079866
SecondaryAll-cause Mortality at Day 14

Day 0 refers to the data of randomization/first treatment.

Time frame:
Mortality at day 14 (initiation of treatment = day 0)
Reported as:
Count of participants · Participants
All-cause Mortality at Day 14
Participants700mg LeronlimabPlacebo700mg open label
All-cause Mortality at Day 14251317
SecondaryProportion of Patients Achieving a Category of 6 or Higher on the Ordinal Scale at Days 14 and 28 (on a 7 Point Ordinal Scale).

Evaluation of the clinical status of participants at Day 28 was assessed with a 7-level ordinal scale (OS) (with higher score indicating better outcome). The OS of patient health status ranged from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. The study enrolled hospitalized patients with an OS Score of 2, 3, or 4 at baseline. The OS score of 6 refers to a participant who is not hospitalized with limitation on activities and 7 refers to not hospitalized with no limitations on activities.

Time frame:
Change from baseline to days 14 and 28
Reported as:
Number · Proportion of patients
Proportion of Patients Achieving a Category of 6 or Higher on the Ordinal Scale at Days 14 and 28 (on a 7 Point Ordinal Scale).
Proportion of patients700mg LeronlimabPlacebo700mg Open Label
Responders at d280.580.550.46
Non-responders at d280.410.450.47
Missing at d28000.07
Responders at d140.380.420.39
Non-responders at d140.620.580.47
Missing at D14000.13
SecondaryChange in Clinical Status of Subjects at Day 28 (on a 7 Point Ordinal Scale)

Evaluation of the clinical status of participants at Day 28 was assessed with a 7-level ordinal scale (OS) (with higher score indicating better outcome). The OS of patient health status ranged from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. The study enrolled hospitalized patients with an OS Score of 2, 3, or 4 at baseline. Baseline is last available value before treatment. Change from baseline is based on patients with paired values. The p value is from rank ANCOVA model adjusted for stratification factor and age using imputed data. All results and change from baseline are based on the result of multiple imputation.

Time frame:
Change from start of treatment (baseline) to day 28
Reported as:
Mean · score on a scale
Change in Clinical Status of Subjects at Day 28 (on a 7 Point Ordinal Scale)
score on a scale700mg LeronlimabPlacebo700mg Open Label
Change in Clinical Status of Subjects at Day 28 (on a 7 Point Ordinal Scale)1.5 ± 2.251.4 ± 2.181.0 ± 2.1
SecondaryLength of Hospital Stay

Length of Hospital Stay measured in days

Time frame:
Timeframe is from screening visit to end of treatment (visit 5)
Reported as:
Median · Days
Length of Hospital Stay
Days700mg LeronlimabPlacebo700mg Open Label
Length of Hospital Stay15 (1 to 45)14 (1 to 46)14 (1 to 45)
Other pre-specifiedAll-Cause Mortality at Day 14 in the Critically Ill Population

All-cause mortality at day 14 in the critically ill population. Day 0 refers to the date of randomization/first treatment.

Time frame:
Mortality at day 14 (initiation of treatment = day 0)
Reported as:
Count of participants · Participants
All-Cause Mortality at Day 14 in the Critically Ill Population
Participants700mg LeronlimabPlacebo
All-Cause Mortality at Day 14 in the Critically Ill Population25

Adverse events

Collected over Study drug was administered at Visit 2 (day 0) and visit 4 (day 7). Adverse events and medications were monitored throughout the study from Visit 2 (day 0, first treatment) through completion of follow up which is Visit 7, (4 weeks after the End of Treatment visit) for a total of 42 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo31/125 (24.8%)47/125 (37.6%)77/125 (61.6%)
700mg Leronlimab60/259 (23.2%)99/259 (38.2%)142/259 (54.8%)
700mg Open Label23/89 (25.8%)35/89 (39.3%)29/89 (32.6%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlacebo700mg Leronlimab700mg Open Label
Respiratory, Thoracic and Mediastinal DisordersRespiratory, thoracic and mediastinal disorders23/12561/25930/89
Infections and InfestationsInfections and infestations25/12538/25910/89
Cardiac DisordersCardiac disorders12/12522/2597/89
Renal and Urinary DisordersRenal and urinary disorders12/12516/2594/89
Vascular DisordersVascular disorders0/1254/2593/89
Nervous System DisordersNervous system disorders4/1256/2591/89
InvestigationsInvestigations3/1257/2590/89
Metabolism and NutritionMetabolism and nutrition disorders3/1256/2592/89
Gen Disorders and Admin Site ConditionsGeneral disorders3/1255/2590/89
Gastrointestinal DisordersGastrointestinal disorders3/1254/2590/89
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlacebo700mg Leronlimab700mg Open Label
Respiratory, Thoracic And Mediastinal DisordersRespiratory, thoracic and mediastinal disorders33/12576/25913/89
Infections And InfestationsInfections and infestations34/12560/25912/89
InvestigationsInvestigations23/12526/2591/89
Metabolism And Nutrition DisordersMetabolism and nutrition disorders21/12546/25912/89
Cardiac DisordersCardiac disorders21/12536/25910/89
Gastrointestinal DisordersGastrointestinal disorders18/12517/2594/89
Vascular DisordersVascular disorders17/12521/2595/89
Blood And Lymphatic System DisordersBlood and lymphatic system disorders15/12527/2595/89
Renal And Urinary DisordersRenal and urinary disorders15/12530/2595/89
Nervous System DisordersNervous system disorders14/12515/2592/89

Baseline characteristics

Baseline population is modified intent to treat population

Age, Categorical
Age, Categorical(Participants)700mg LeronlimabPlacebo700mg Leronlimab - open labelTotal
<=18 years0000
Between 18 and 65 years1719657324
>=65 years882932149
Age, Continuous
Age, Continuous(years)700mg LeronlimabPlacebo700mg Leronlimab - open labelTotal
Mean58.82 (20 to 88)58.51 (28 to 86)59.18 (23 to 85)58.72 (20 to 88)
Sex: Female, Male
Sex: Female, Male(Participants)700mg LeronlimabPlacebo700mg Leronlimab - open labelTotal
Female904225157
Male1698364316
Race (NIH/OMB)
Race (NIH/OMB)(Participants)700mg LeronlimabPlacebo700mg Leronlimab - open labelTotal
American Indian or Alaska Native1001
Asian117119
Native Hawaiian or Other Pacific Islander0000
Black or African American29231769
White1337054257
More than one race85250110
Unknown or Not Reported001717
Region of Enrollment
Region of Enrollment(participants)700mg LeronlimabPlacebo700mg Leronlimab - open labelTotal
United States25912589473
COVID SYMPTOM SCORE
COVID SYMPTOM SCORE(units on a scale)700mg LeronlimabPlacebo700mg Leronlimab - open labelTotal
Mean3.2 (2.0 to 4.0)3.2 (2.0 to 4.0)3.3 (2.0 to 4.0)3.2 (2.0 to 4.0)
08

Study locations

18 sites
  • Advanced Cardiovascular, LLC
    Alexander City, Alabama 35010, United States
  • St. Jude Medical Center
    Fullerton, California 92835, United States
  • UCLA
    Los Angeles, California 90095, United States
  • James A. Haley Veterans' Hospital
    Tampa, Florida 33612, United States
  • Center for Advanced Research & Education (CARE)
    Gainesville, Georgia 30501, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • St. Barnabas
    Livingston, New Jersey 07052, United States
  • Atlantic Health System Hospital
    Morristown, New Jersey 07962-1905, United States
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
  • New York Community Hospital of Brooklyn
    Brooklyn, New York 11229, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • Novant Health
    Winston-Salem, North Carolina 27103, United States
  • Ohio Health
    Columbus, Ohio 43215, United States
  • Good Samaritan Hospital Corvallis
    Corvallis, Oregon 97330, United States
  • Oregon Health and Sciences University
    Portland, Oregon 97239, United States
  • Baylor Scott & White Research Institute
    Dallas, Texas 75204, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Texas
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Welch J, Dean J, Hartin J. Using NEWS2: an essential component of reliable clinical assessment. Clin Med (Lond). 2022 Nov;22(6):509-513. doi: 10.7861/clinmed.2022-0435. PubMed 36427875 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Oct 2021, 18 months.

Results were first posted in Aug 2025, 3 years 10 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 18 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2020
First posted
Apr 15, 2020
StartActual
Apr 16, 2020
Primary completionActual
Oct 24, 2021
CompletionActual
Jun 15, 2022
Results first posted
Aug 27, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04347239
Lead sponsor
CytoDyn, Inc.
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
Apr 16, 2020
Primary completion
Oct 24, 2021
Completion
Jun 15, 2022
Results posted
Aug 27, 2025
Last update
Oct 15, 2025

Study contacts

Jacob Lalezari, MD
study director · CytoDyn, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion